Alimera Sciences Inc
NASDAQ:ALIM

Watchlist Manager
Alimera Sciences Inc Logo
Alimera Sciences Inc
NASDAQ:ALIM
Watchlist
Price: 5.54 USD -0.18%
Market Cap: 301.3m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

ALIM Price Targets Summary
Alimera Sciences Inc

There are no price targets for ALIM.
ALIM Lowest Forecast
Wall Street Target
Not Available
ALIM Average Forecast
Wall Street Target
Not Available
ALIM Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Alimera Sciences Inc Competitors:
Price Targets
APLLTD
Alembic Pharmaceuticals Ltd
0% Downside
NEU
Neuren Pharmaceuticals Ltd
80% Upside
2161
Jbm (Healthcare) Ltd
7% Upside
F
FAE
Faes Farma SA
8% Upside
APLLTD
Alembic Pharmaceuticals Ltd
0% Downside
NEU
Neuren Pharmaceuticals Ltd
80% Upside
2161
Jbm (Healthcare) Ltd
7% Upside
F
FAE
Faes Farma SA
8% Upside
H
200670
Humedix Co Ltd
6% Upside
CIPLA
Cipla Ltd
14% Upside
ANCR
Animalcare Group PLC
19% Upside
4886
ASKA Pharmaceutical Holdings Co Ltd
9% Upside

Revenue
Forecast

Revenue Estimate
Alimera Sciences Inc

For the last 8 years the compound annual growth rate for Alimera Sciences Inc's revenue is 17%. The projected CAGR for the next 3 years is 20%.

17%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Alimera Sciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Alimera Sciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-89%
Average Miss
What are analyst estimates?

See Also

Summary
ALIM intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALIM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALIM stock valuation using valuation multiples.
Wall Street Estimates
ALIM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALIM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ALIM's stock price target?
Not Available

ALIM doesn't have any price targets made by Wall Street professionals.

What is Alimera Sciences Inc's Revenue forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Alimera Sciences Inc's revenue is 17%. The projected CAGR for the next 3 years is 20%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 267,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.